These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 16059626)

  • 21. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
    Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
    Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
    Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
    Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
    J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
    Watanabe Y; Ohshima H; Mizuno K; Sekiguchi C; Fukunaga M; Kohri K; Rittweger J; Felsenberg D; Matsumoto T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1771-8. PubMed ID: 15476576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.
    Amir E; Freedman O; Carlsson L; Dranitsaris G; Tomlinson G; Laupacis A; Tannock IF; Clemons M
    Am J Clin Oncol; 2013 Oct; 36(5):436-42. PubMed ID: 22781385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamidronate distribution in pediatric renal and rheumatologic patients.
    Acott PD; Wong JA; Crocker JF; Lang B; O'Regan P; Renton KW
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1013-9. PubMed ID: 17024486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
    Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
    J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
    Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
    Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
    J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2009 Aug; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.